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The calcium-dependent lipopeptide antibiotics:
structure, mechanism, & medicinal chemistry
Thomas M. Woodab and Nathaniel I. Martin *b
To push back the growing tide of antibacterial resistance the discovery and development of new antibiotics
is a must. In recent years the calcium-dependent lipopeptide antibiotics (CDAs) have emerged as a poten-
tial source of new antibacterial agents rich in structural and mechanistic diversity. All CDAs share a com-
mon lipidated cyclic peptide motif containing amino acid side chains that specifically chelate calcium. It is
only in the calcium bound state that the CDAs achieve their potent antibacterial activities. Interestingly, de-
spite their common structural features, the mechanisms by which different CDAs target bacteria can vary
dramatically. This review provides both a historic context for the CDAs while also addressing the state of
the art with regards to their discovery, optimization, and antibacterial mechanisms.
1. Introduction
The rapid emergence and onset of drug-resistant bacteria is
now considered one of the most urgent global threats to hu-
man health.1 In 2017 the Center for Disease Control and Pre-
vention (CDC) revealed that more than 2 million people ac-
quire an antibiotic-resistant infection per year which leads to
at least 23 000 deaths in the US alone.2 The pernicious in-
crease in the incidence of multi-drug-resistant (MDR) Gram-
negative bacteria that are resistant to carbapenems3,4 and co-
listin5,6 in Enterobacteriaceae is considered a top priority by
the CDC. The same holds true for infections caused by Gram-
positive pathogens as exemplified by the infamous hospital
bacteria methicillin-resistant Staphylococcus aureus (MRSA)7,8
and vancomycin-resistant enterococci (VRE).9 These develop-
ments have seen a steady decline in the availability of clini-
cally approved antibiotics that are effective at combating
MDR pathogens, leading some to speculate that the antibiotic
era is coming to an end.10,11 During the so-called golden age
of antibiotic discovery (1940s–1960s) a myriad of powerful
and structurally unique antibiotics were discovered and
brought to the clinic, including: sulfonamides, β-lactams,
aminoglycosides, glycopeptides, macrolides, tetracyclines,
chloramphenicol, lincosamides, quinolones and
streptogramins.12 However, the decades that followed (1970s–
2000s) are now known as the “discovery void” with only two
new classes of structurally and mechanistically distinct antibi-
otics being discovered in this period as the pipeline of readily
available antibiotics from nature dried up.13 Notably, the
calcium-dependent lipopeptide antibiotic daptomycin is one
of a rare number of first in class antibiotics to have entered
the market since the year 2000.14,15
In this review we present a comprehensive summary of
the calcium-dependent lipopeptide class of antibiotics
(CDAs), with a primary focus on their structural features,
antibacterial mechanisms and clinical potential. As the only
currently clinically approved CDA, daptomycin (Fig. 1) is a
special and representative case. First discovered by re-
searchers at Eli Lily in 1983, daptomycin was later
shepherded through clinical development by Cubist pharma-
ceuticals, gaining approval as cubicin in 2003 for the treat-
ment of skin infections caused by Gram-positive bacteria and
later in 2006 for bloodstream (bacteremia) infections caused
by MRSA.15,16 Industrially, daptomycin is produced by the fer-
mentation of Streptomyces roseosporus supplemented with
decanoic acid to favor production of the compound
containing the desired C10-fatty acid.16,17 In the years 2006–
2014 annual sales of daptomycin reached 1 billion dollars
making it a rare example of a blockbuster antibiotic drug.
Based on these strong sales figures, Merck acquired Cubist in
2014 for a sum of 9.5 billion USD. As of 2016 daptomycin is
off patent and various generic versions are now available.
While daptomycin is the most renowned CDA, there are sev-
eral other cyclic lipoĲdepsi)peptides of the same family that dis-
play potent antibacterial activity. These include a number
of depsipeptides produced by Streptomyces coelicolor A(3)2
(ref. 18) and A 54145 produced by Streptomyces fradiaei.19
Other CDAs include the amphomycin,20 friulimicin,21 and
laspartomycin/glycinocin22,23 classes which are also produced
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by various other streptomycetes.24 As illustrated by the struc-
ture of daptomycin (Fig. 1) nearly all CDAs share the same posi-
tioning of constituent D-amino or achiral amino acids in addi-
tion to a highly conserved Asp-X-Asp-Gly motif.25 This Asp-X-
Asp-Gly sequence is imperative for calcium binding, which is
needed for achieving full antibacterial activity as in the absence
of calcium, the activity of the CDAs is significantly reduced.25
The structures of all CDAs consist of two main components: a
cyclic peptide macrocycle and a long-chain fatty acid tail which
is linked to the peptide core. In nature CDAs are produced by
nonribosomal peptide synthetases (NRPSes). A number of ex-
cellent previous reviews provide in-depth information regard-
ing the biosynthetic pathways and the specific enzymes in-
volved in CDA production.24,25 In this review we will therefore
focus more on the structure and mechanistic aspects of the
CDAs as well as recent medicinal chemistry approaches to gen-
erating new analogues of these compounds and advanced
screening techniques to identify novel family members.
2. Clinically used CDAs and
compounds in advanced development
Daptomycin is the only clinically approved CDA and is pri-
marily prescribed for the treatment of serious Gram-positive
infections. The dosing of daptomycin is based on individual
body weight and shows a concentration-dependent mode of
action.15 Produced industrially by fermentation of the actino-
mycete Streptomyces roseosporus, daptomycin is actually
formed as member of the so-called A21978C complex of
structurally related CDAs (Fig. 2). All members of the
A21978C complex consists of the same 13 amino acid peptide
and are exemplified by their ten-membered ring which is
achieved by macrolactonization between Thr4 and Kyn13.16
Other unique D- and non-proteinogenic amino acids present
include: D-Asn2, D-Ala4, ornithine (Orn6), D-Ser11 and
3-methylglutamic acid (MeGlu12).25 The CDAs of the A21978C
complex differ only in their aliphatic lipid tails and Fig. 2
Fig. 1 Structure of daptomycin indicating N-terminal lipid in red and in blue the calcium binding motifs. The peptide macrocycles are formed bio-
synthetically via cyclization of the C-terminal residue with the side chain of Thr4 (linkages shown in green).
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illustrates this structural variation. Interestingly, daptomycin
was initially identified as a minor component of the A21978C
complex but demonstrated superior biological activity when
compared with the other members of the complex.26 This led
to an optimization of the production process whereby addi-
tion of exogenous decanoic acid to fermentation of S.
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roseosporus results in an increased production of
daptomycin.27
Despite its clinical importance, the precise working
mechanism by which daptomycin kills bacteria has yet to
be fully elucidated. Over the past decade numerous studies
have attempted to pinpoint its mechanism of action
resulting in various, and in some cases conflicting models.
These models range from calcium-dependent oligomeriza-
tion and phosphatidylglycerol-mediated membrane pore for-
mation, to alteration of membrane fluidity and inhibition of
cell wall synthesis.28–30 Despite the continuing debate over
its specific mechanism of action, daptomycin has been used
for more than a decade in the clinic and reports are now
emerging of resistance in strains of both E. faecium31 and
MRSA.32 Resistance to daptomycin stems from mutation in
a number of bacterial genes. These genes generally activate
the pathogen's defenses to cell wall damage and stress as
the bacterial cell attempts to prevent daptomycin from
reaching the cytoplasmic membrane. Mutations in such
genes can in turn result in increased MIC.33 Notably, clini-
cal isolates from patients failing to respond to daptomycin
therapy have shown frequent accumulation of mprF point
mutations in S. aureus. The encoded protein MprF, is a
transmembrane protein that caps phosphatidylglycerol in
the cell membrane with lysine, thus reducing the net nega-
tive charge of the cell surface.34
The first total chemical synthesis of daptomycin was
achieved by researchers at Cubist Pharmaceuticals in 2006
and appears only in the patent literature.35 The Cubist team
employed a convergent approach (Scheme 1) wherein one
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peptide fragment containing the synthetically challenging es-
ter linkage between Thr4 and Kyn13 was coupled to a second
resin bound peptide fragment attached to a solid support via
the side chain of MeGlu12. Prudent use of alloc and allyl es-
ter protecting groups and temporary azide masking of the an-
iline nitrogen of the kynurenine unit in the coupled fragment
enabled the subsequent simultaneous deprotection/reduction
of the resin bound intermediate using palladium catalysis.
Following on-resin cyclization and cleavage/deprotection
daptomycin was isolated in moderate yield. A second total
synthesis of daptomycin was reported by the group of Li in
2013 who employed a similar convergent route combining
solid- and solution-phase approaches with a chemoselective
serine ligation providing the key cyclization step of the
macrocycle (Scheme 2).36,37 Also notable in the Li synthesis
was the practical introduction of an appropriately protected
kynurenine by ozonolysis of the corresponding N-Boc-
protected Trp. Judicious use of azide chemistry also provided
the requisite orthogonality for elaboration of the resin bound
peptide. More recently, Taylor and coworkers described an
concise approach to synthesizing daptomycin entirely on
solid support enabling the rapid synthesis of other
daptomycin analogues (Scheme 3).38,39 To enable the total
SPPS approach Taylor's group employed an elegant protecting
group strategy, including a number of azide masked amino
acid building blocks, as well as optimized Fmoc deprotection
conditions to protect the sensitive ester linkage.
Semisynthetic approaches have also been used to produce
daptomycin analogues with improved MIC profiles compared
to that of the parent compound.40 Structure–activity relation-
ship studies on the fatty acid tail revealed several critical fac-
tors for antimicrobial activity: lipophilicity, chain length and
the location of key aromatic functionalities.40,41 The acyl tail
is crucial for binding to the bacterial cell membrane and
calcium-dependent insertion.42 One such semisynthetic ana-
logue thus developed is surotomycin (Fig. 3) which differs
from daptomycin only in the structure of its lipid tail. In
surotomycin the lipid tail contains a conjugated substituted
alkene and an aromatic moiety that was found to give en-
hanced activity against C. difficile. To date, two registered
phase III clinical studies have been completed with
surotomycin.43,44 Both were randomized, double blind, multi-
center, global studies in adult patients with C. difficile-associ-
ated diarrhea. In these studies, the efficacy of surotomycin
was compared to that of vancomycin for 10 day treatment
regimens. At their conclusion these trials revealed that while
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surotomycin was generally well tolerated, it did not meet the
primary efficacy endpoint of noninferiority compared to that
of vancomycin. It also failed to meet the secondary end-
points, i.e. superiority over vancomycin and sustained clinical
response at the end of the trial.
The lipodepsipeptides daptomycin and surotomycin are not
the only CDAs to have been taken to clinical trials. Two others,
amphomycin and friulimicin (Fig. 4), both belonging to a struc-
turally distinct lipopeptide sub class of CDAs, have been evalu-
ated as human therapeutics. Discovered in the 1950s,
amphomycin was the first CDA reported in the literature.20 In
the years following, a myriad of similar or identical compounds
have been reported under different names, which has led to sig-
nificant confusion in the nomenclature associated with the
class.24,25,45,46 The reader is referred to a comprehensive 2005
review by Baltz and coworkers that serves to clarify much of the
Fig. 3 Structure of surotomycin. This semisynthetic analogue of daptomycin bears an unnatural lipid tail imparting potent activity against C. difficile.
Fig. 4 Structures of the (A) friulimicin and (B) amphomycin families of CDA. Indicated in brackets are the carious other names that have
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ambiguity associated with this group of CDAs.21,24 Typically
these lipopeptides are subdivided into three subclasses, the
amphomycins, the friulimicins and the laspartomycins. As indi-
cated in Fig. 4, there is a logical convention used in the naming
of the various friulimicins as A, B, C, or D depending on the
lipid tail. We respectively propose to apply the same convention
in the nomenclature used for describing the structurally similar
amphomycin class of CDA (see Fig. 4 for proposed nomencla-
ture). The amphomycins and the friulimicins are identical apart
from the exocyclic Asp residue found in the amphomycin class,
which in the friulimicins is instead an Asn. Variation in the
lipid chains is responsible for additional diversity. The structure
of the laspartomycin core peptide differs more significantly and
is discussed in further detail in section 4.
The amphomycins and friulimicins both share the same
macrocyclic peptide consisting of 10 amino acids with cycliza-
tion between the diaminobutyric acid (Dab) at position 2 and
Pro11. Several D- and nonproteinogenic amino acids, such as
L-threo and D-allo-2,3-Dab, D-pipecolic acid (D-Pip) as well as L-
thero-3-methyl-aspartate (MeAsp), are found at positions 2, 9, 3
and 4 in the peptide core respectively. Four main fatty acid tails
are found throughout these compounds, consisting of either 13,
14 or 15 carbon atoms in total. The lipids commonly bear iso or
anteiso branching groups at their terminal ends and all contain
an unsaturated double bond between carbon three and four.
As is common to nearly all the CDAs, the amphomycin,
friulimicin and laspartomycin lipopeptides contain the same
Asp-X-Asp-Gly calcium binding motif as daptomycin. Despite
this structural similarity, several investigations have revealed
that the amphomycins, friulimicins, and laspartomycins oper-
ate via a mechanism different than that of daptomycin. Early
studies with amphomycin indicated that it interferes with the
first membrane associated step of bacterial cell wall biosynthe-
sis by disrupting the transfer of the soluble UDP cell wall pre-
cursor to the phospholipid membrane anchor undecaprenyl
phosphate (C55-P).
47 More recent studies have revealed that
members of this class of CDA form tight complexes with C55-P
as a major driver of their antibacterial mechanisms.48,49
As stated above, both amphomycin and friulimicin have
been investigated as possible leads for antibiotic drug devel-
opment. To this end a semisynthetic analogue of
amphomycin, MX-2401 (Fig. 5), was recently brought to clini-
cal trials by BioWest Therapeutics Inc. for the treatment of
serious Gram-positive infections.50,51 Compared to
amphomycin, MX-2401 is rapidly bactericidal and was shown
to be effective in several infections models with potent activ-
ity against VRSA, VRE and MRSA.48,49 Recent NMR studies
demonstrated that S. aureus cells treated with MX-2401 ex-
hibit a thinning of the cell wall, a decrease in D-alanine
linked teichoic acids, and a reduction in peptidoglycan cross-
linking.52 Although MX-2401 reached late stage preclinical
development it has never been tested in human patients in a
clinical setting. By comparison, in 2007 MerLion Pharmaceu-
ticals initiated phase I clinical trial studies with friulimicin B.
However, the trial was terminated soon thereafter due to un-
favorable pharmacokinetics.
3. The A54145 and CDA classes
A54145 is a lipodepsipeptide like daptomycin and the A21978
family but is much more structurally complex (Fig. 6). The
A54145 group is produced by Streptomyces fradiae and shows
Fig. 5 Structure of the semisynthetic amphomycin analogue MX-2401. Highlighted in red is the 4-(dodecanamido)benzoic acid lipid tail and in
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antibacterial activity against various strains of Staphylococcus
aureus, Staphylococcus epidermidis, Clostridium, Streptococcus,
and enterococci.19,53 The lipid tails of the A54145 family are
fully saturated and often terminate with iso or anteiso
branching patterns.19 The structural complexity of the
A54145 group is found in their peptide sequences. Seven of
the thirteen component amino acids are nonproteinogenic
including three D-amino acids. Six of the seven unique amino
acids (D-Glu2, 3-hydroxy-L-aspragine (hAsn3), sarcosine (Sar5),
D-Lys8, 3-methoxyAsp (MeO-Asp9) and D-Asn11) are found in
all members of the A54145 family. In addition, a MeGlu resi-
due is found at position 12 in four of the known A54145 pep-
tides and position 13 is either an Ile or a Val giving rise to ad-
ditional structural variation.53,54 A54145 is homologous to
daptomycin and permeabilizes the cell membrane of Gram-
positive bacteria in a similar fashion. As for daptomycin,
membrane permeabilization depends on the presence of cal-
cium and phosphatidylglycerol and leads to the formation of
oligomeric membrane pores that consist of 6–8 individual
subunits.55,56
In 1983 a new class of calcium-dependent antibiotics pro-
duced by Streptomyces coelicolor was discovered and given
the general family name CDA which subsequently led to
some confusion in the field.18 These CDAs from S. coelicolor
were later structurally characterized and found to belong to
the same class of lipodepsipeptides as daptomycin and the
A54145 family (Fig. 7).57 However, unlike daptomycin and the
A54145s, in the so named CDA group the exocyclic motif con-
sist of a single amino acid (Ser) and the fatty acid acyl tail is
exclusively found to be 2,3-epoxy-hexanoyl.57,58 A high degree
of structural variation is found within the macrocycles of the
CDA peptides. Most notable is the D-hydroxy asparagine at
position 9, in which the beta-hydroxyl is phosphorylated in
CDA1 and CDA2. Two additional D-amino acids, D-Trp and D-
4-hydroxyphenylglycine, are found at positions 3 and 6 respec-
tively. Position 10 is either a Glu or 3-methyl-Glu. Another
Fig. 6 Structures of A54145 class of CDAs.
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unique site of structural variation is found in the side chain
of Trp-11: in CDA2a, CDA3a, ACD4a and CDAfa, Trp-11 is de-
hydrogenated to Z-2,3-dehydrotryptophan (ΔTrp).58
4. Emerging insights and recent
developments
Recent studies conducted both in the Payne group59 as well
as our own60 have focused on the synthesis and mechanism
of action of the laspartomycin family of the CDAs. The
laspartomycins belong to the same sub-family as the
amphomycins/friulimicins and the first laspartomycin to be
reported was isolated from Streptomyces viridochromogenes in
1968.22 Due to the analytical constraints of the time, a full
chemical characterization was not reported until 2007 when
advanced purification techniques and spectroscopic methods
led to the structure elucidation of the major component,
laspartomycin C.23 Somewhat parallel to this work, investiga-
tions aimed at identifying the active antibiotic components
in the fermentation broth of an unidentified terrestrial acti-
nomycetes species led to the discovery of the so-called
glycinocin family of the CDAs.61 The glycinocins were subse-
quently shown to be largely identical to the laspartomycins
with the dominant glycinocin A sharing the exact same struc-
ture as laspartomycin C (Fig. 8). Among the other glycinocins
characterized, glycinocin B and C have the same peptide core
as laspartomycin C and only differ in the length of their fatty
acid, with the lipids both consisting of iso branching at the
terminal end. Glycinocin D has the same lipid tail as
laspartomycin C however, in place of a Ile at position 10, it
contains Val (as for the amphomycins and friulimicins).61
Unlike the amphomycins and friulimicins, in both the
laspartomycin and glycinocin classes, a diaminopropionic
acid residue (Dap2) facilitates macrolactamization rather
than 2S,3R-diaminobutyric acid (Dab2). Other differences
include D-allo-Thr9 in place of 2R,3R-D-Dab9, and a simple Gly
at position 4 instead of non-proteinogenic MeAsp4. Further-
more, the fatty acid of the laspartomycin/glycinocin family is
2,3-unstaurated and has E geometry versus the 3,4-
unsaturation with Z geometry observed in the amphomycin
and friulimicin families. Laspartomycin C shows antibacterial
activity against a variety of Gram-positive pathogens includ-
ing MRSA, VRE and VRSA.22,62 To further examine its poten-
tial as an antibiotic lead compound, a number of semisyn-
thetic laspartomycin variants have been reported by
incorporating a number of different lipid tails.62 These stud-
ies revealed that both the length and saturation of the lipid
tail is essential for full activity.
While laspartomycin C shares many structural similarities
with the amphomycins and friulimicins the mechanistic de-
tails of its antibacterial mode of action remained unknown
until recently elucidated by our group in 2016.60 In doing so
we also developed a convenient combined solid- and
solution-phase approach for the synthesis of laspartomycin C
and structural analogues (Scheme 4). Notably, our synthesis
of laspartomycin C represents only the second CDA to be pre-
pared via total synthesis. Soon thereafter Payne and co-
workers reported a similar approach to the synthesis of
glycinocins A–C and variants thereof.63 Using our synthetic
laspartomycin we demonstrated that it specifically and tightly
binds undecaprenyl phosphate (C55-P) a bacterial phospho-
lipid essential for cell wall synthesis. Using isothermal titra-
tion calorimetry, we quantified C55-P binding laspartomycin
with a remarkably low nanomolar Kd value. Building upon
this work, in a collaboration with the Janssen group, we re-
cently solved the crystal structure of laspartomycin C bound
to a more soluble truncated analogue of C55-P, geranyl phos-
phate (C10-P).
64 The structure reveals a basic unit comprised
of a 1 : 2 : 1 laspartomycin C/Ca2+/C55-P stoichiometry (Fig. 9).
The structure also suggests that a dimeric species may be
biologically relevant wherein two laspartomycin C fatty acid
side chains and two C10-P tails orientated perpendicular to a
hydrophobic plane. The phosphate head groups are then se-
questered within the core of laspartomycin C dimer which
lies slightly embedded in the bacterial membrane. While a
previous crystal structure of tsushimycin (amphomycin B
according to the nomenclature proposed in Fig. 4) provided
insight into calcium binding,65 our laspartomycin C structure
Fig. 8 Laspartomycin C and the glycinocin A–D family. Highlighted in blue is the conserved Asp-X-Asp-Gly Ca2+ binding motif and highlighted in
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represents the first structure of a CDA bound to both calcium
and its biomolecular target.
Advancements in the field of next-generation sequencing
technologies have shed new light on microbial genomes as a
potentially rich source for novel antibiotics. In a recent report
from the Moore group, a transformation-associated recombi-
nation cloning technique was used to clone, refactor, and ex-
press a silent biosynthetic pathway to yield two CDAs named
taromycin A and taromycin B (Fig. 10).66,67 While taromycin
is structurally similar to daptomycin it also contains two
chlorinated amino acids, namely a 6-chloro-tryptophan at po-
sition 1 and a 4-chloro-kynuenine at position 13. While these
chlorinated amino acids are not found in any other CDAs,
they do not seem to offer a significant advantage as the activ-
ity of taromycin does not match or surpass that of
daptomycin.
In another demonstration of the power of microbial ge-
nome mining, Brady and co-workers recently reported an en-
tirely new class of CDAs, termed the malacidins (Fig. 11A).68
The malacidins are unique among the CDAs in that they lack
the canonical Asp-X-Asp-Gly calcium binding motif which is
instead replaced by the tri-peptide β-hydroxy-Asp-Asp-Gly.
This change results in the malacidins having a nine amino
acid peptide macrocycle rather than the ten amino acid
macrocycle found in all other CDAs. Despite this difference,
the malacidins demonstrate a strong calcium dependence for
their antibacterial activity. Also, of note is the unique mecha-
nism of action of the malacidins. Unlike the other CDAs, that
act by membrane disruption (daptomycin, A54145, CDA) or
by binding C55-P to inhibit cell-wall biosynthesis
(amphomycins, friulimicins, laspartomycins), the malacidins
inhibit bacterial cell-wall biosynthesis by binding to lipid II.68
The activity of the malacidins are on par with that of
daptomycin, with MICs of 0.2–0.8 μg mL−1 against MRSA and
0.8–2.0 μg mL−1 against VRE. Malacidin's in vivo activity was
Scheme 4 Combined solution- and solid-phase approach used by our group in the first total synthesis of laspartomycin C.
Fig. 9 Crystal structure of laspartomycin C (green stick
representation) bound to two bound Ca2+ ions (orange spheres) and
the geranyl monophosphate ligand coordinated by the Ca2+ ions. The
two Ca2+ ions are labelled A (red) and B (blue) with the interacting
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also assessed in a rat cutaneous wound model where it suc-
cessfully cleared MRSA infection.
Very recently, the Brady group reported another new
member of the CDA family which they also identified using
genome mining approaches and named the cadasides
(Fig. 11B).69 Similar to the malacidins, the cadasides con-
tain a nine amino macrocycle however, unlike the
malacidins, the cycle is closed via an ester linkage to yield a
depsipeptide. Also of note, while the malacidin lipid tail
bears an E,Z unsaturation pattern, that of the cadasides
Fig. 10 Taromycin A and B. Highlighted in orange are the chlorinated amino acids 6-chloro-tryptophan and 4-chloro-kynurenine. The taromycin
family has a D-alanine in place of the D-serine found in daptomycin (highlighted in blue).
Fig. 11 Structures of A) the malacidins and B) the cadasides. Highlighted in orange are the nonproteinogenic amino acids and highlighted in blue
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contains the reversed Z,E geometry. The cadasides also lack
the canonical calcium binding Asp-X-Asp-Gly motif found in
other CDAs but do contain a β-hydroxy-Asp and a γ-hydroxy-
Glu within their macrocycle. It is tempting to speculate that
one or both of these hydroxylated amino acids may play a
role in calcium binding. However, this hypothesis remains
to be investigated experimentally. While metagenomic based
antibiotic discovery is still in its infancy it may prove to be
a useful tool in discovering new CDAs that are hidden in so
called cryptic gene clusters.
5. Conclusions
The spread of multi-drug-resistant bacteria remains a con-
cern and presents a serious threat to modern healthcare.
While the first CDA was reported in the early 1950s, it was
the approval of daptomycin in 2003 that brought this
unique class of antibiotics into the spotlight. Enabled by ad-
vances in screening and synthetic chemistry, the past de-
cade has witnessed a burst of activity in the field. With now
over 40 unique CDAs reported, their structural diversity con-
tinues to provide opportunity for discovery. Of particular
note is the growing appreciation that the different members
of the CDA superfamily utilize a diverse range of anti-
bacterial mechanisms. A more complete understanding of
these different mechanisms, supported by structural in-
sights, will be key to establishing a more complete struc-
ture–activity relationships for the various CDAs. Such infor-
mation is in turn expected to inform the design of
optimized CDAs accessible via synthetic means. While
daptomycin remains the only clinically used CDA, the many
advances and increasing interest in this compound class
suggest there is good reason to expect additional family
members to enter the clinic in the years to come.
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